EXEGI PHARMA Trademark

Trademark Overview

On Thursday, October 9, 2014, a trademark application was filed for EXEGI PHARMA with the United States Patent and Trademark Office. The USPTO has given the EXEGI PHARMA trademark a serial number of 86419162. The federal status of this trademark filing is SECTION 8 & 15 - ACCEPTED AND ACKNOWLEDGED as of Saturday, June 29, 2024. This trademark is owned by EXEGI PHARMA, LLC. The EXEGI PHARMA trademark is filed in the Pharmaceutical Products category with the following description:

Food supplements; Food supplements for treating digestive disorders; Health food supplements; Nutritional supplements, namely, probiotic compositions; Dietary and nutritional supplements; Pharmaceutical preparations for the treatment of inflammatory bowel diseases, ulcerative colitis, irritable bowel syndrome, pouchitis, liver diseases; Drugs, Biologic drugs and live biotherapeutics for the treatment of inflammatory bowel diseases, ulcerative colitis, irritable bowel syndrome, pouchitis, liver disease; Medical Food, namely, dietetic foods in the nature of powder specially adapted for medical use; Probiotic supplements
exegi pharma

General Information

Serial Number86419162
Word MarkEXEGI PHARMA
Filing DateThursday, October 9, 2014
Status702 - SECTION 8 & 15 - ACCEPTED AND ACKNOWLEDGED
Status DateSaturday, June 29, 2024
Registration Number5360299
Registration DateTuesday, December 19, 2017
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 29, 2015

Trademark Statements

Goods and ServicesFood supplements; Food supplements for treating digestive disorders; Health food supplements; Nutritional supplements, namely, probiotic compositions; Dietary and nutritional supplements; Pharmaceutical preparations for the treatment of inflammatory bowel diseases, ulcerative colitis, irritable bowel syndrome, pouchitis, liver diseases; Drugs, Biologic drugs and live biotherapeutics for the treatment of inflammatory bowel diseases, ulcerative colitis, irritable bowel syndrome, pouchitis, liver disease; Medical Food, namely, dietetic foods in the nature of powder specially adapted for medical use; Probiotic supplements
NOT AVAILABLE"PHARMA"

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, October 16, 2014
Primary Code005
First Use Anywhere DateMonday, February 1, 2016
First Use In Commerce DateMonday, February 1, 2016

Trademark Owner History

Party NameEXEGI PHARMA, LLC
Party Type30 - Original Registrant
Legal Entity Type16 - Limited Liability Company
AddressRockville, MD 20850
Party NameEXEGI PHARMA, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressGaithersburg, MD 20878
Party NameEXEGI PHARMA, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressGaithersburg, MD 20878

Trademark Events

Event DateEvent Description
Wednesday, January 28, 2015ASSIGNED TO EXAMINER
Monday, October 13, 2014NEW APPLICATION ENTERED
Thursday, October 16, 2014NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, February 3, 2015NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, February 3, 2015NON-FINAL ACTION E-MAILED
Tuesday, February 3, 2015NON-FINAL ACTION WRITTEN
Friday, August 14, 2015ASSIGNED TO LIE
Thursday, July 30, 2015ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, July 30, 2015TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, July 30, 2015TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, August 21, 2015TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, August 21, 2015CORRESPONDENCE RECEIVED IN LAW OFFICE
Sunday, August 23, 2015APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, August 24, 2015LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, September 9, 2015NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, September 29, 2015PUBLISHED FOR OPPOSITION
Tuesday, September 29, 2015OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 24, 2015NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, May 24, 2016SOU TEAS EXTENSION RECEIVED
Tuesday, May 24, 2016SOU EXTENSION 1 FILED
Tuesday, May 24, 2016SOU EXTENSION 1 GRANTED
Thursday, May 26, 2016NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, August 25, 2016TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, November 23, 2016SOU TEAS EXTENSION RECEIVED
Wednesday, November 23, 2016SOU EXTENSION 2 FILED
Tuesday, December 13, 2016CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, December 13, 2016SOU EXTENSION 2 GRANTED
Wednesday, December 14, 2016NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, May 24, 2017TEAS STATEMENT OF USE RECEIVED
Wednesday, May 24, 2017USE AMENDMENT FILED
Monday, June 5, 2017STATEMENT OF USE PROCESSING COMPLETE
Tuesday, June 6, 2017SU - NON-FINAL ACTION - WRITTEN
Tuesday, June 6, 2017NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, June 6, 2017NON-FINAL ACTION E-MAILED
Friday, November 10, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, November 10, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, November 10, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, November 13, 2017ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Tuesday, December 19, 2023TEAS SECTION 8 & 15 RECEIVED
Saturday, June 29, 2024CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Saturday, June 29, 2024REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Saturday, June 29, 2024NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Monday, December 19, 2022COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Tuesday, November 14, 2017NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, December 19, 2017REGISTERED-PRINCIPAL REGISTER

Related Keywords

pharma exegi supplements food bowel diseases colitis inflammatory irritable syndrome medical drugs